Posted by Michael Wonder on 12 May 2021
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
12 May 2021 - Japanese pharma company Astellas has announced that its prostate cancer therapy Xtandi has gained an approval for an additional indication from the UK’s Medicines and Healthcare products Regulatory Agency.
The additional indication is for once daily oral Xtandi (enzalutamide) for the treatment of adult men with metastatic hormone-sensitive prostate cancer.
